HOUSTON, TX / ACCESS Newswire / February 11, 2025 / EON Resources Inc. (NYSE American:EONR) ("EON" or the "Company") announced it has entered into an agreement with Pogo Royalty, LLC ("Pogo" or "Seller") that would result in a restructure of EON's balance sheet through (a) the retirement of a promissory note to Seller having an original principal amount of $15,000,000, (b) the purchase of a 10% Overriding Royalty Interest ("ORRI") in the Company's oil field property from Seller and (c) the repurchase of 100% of preferred units held by Seller in EON's subsidiary which would otherwise convert into the Company's …

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Edison International ("Edison International") (NYSE:EIX) concerning possible violations of federal securities laws. On January 12, 2025, the Los Angeles Times published an article, "Officials investigating whether Southern California Edison equipment ignited Hurst fire.

Collaboration to provide Firefly with the technical resources to help further unleash the power of its FDA-cleared BNA™ platform

Medicus Pharma Ltd.'s shares will remain listed on the NASDAQ Capital Market Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - February 11, 2025) - Medicus Pharma Ltd.

I believe Alibaba's newly released Qwen LLM might bring great potential to enterprise applications development. China's macroeconomic landscape resembles the US post-2008, with quantitative easing and low bond yields driving capital back to equities, favoring large-cap stocks like Alibaba. Alibaba's recent developments may signal a massive reversal driven by AI-related revenue growth acceleration and better margins coming from optimized e-commerce processes.

My Income Never Stops, 12% Yield: Annaly Capital

MILWAUKEE--(BUSINESS WIRE)--Ademi & Fruchter LLP is investigating Playa (NASDAQ: PLYA) for possible breaches of fiduciary duty and other violations of law in its transaction with Hyatt. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Playa stockholders will receive only $13.50 per share, or approximately $2.6 billion, including appro.

Humana Tuesday reported $1.2 billion in 2024 profits that included a $693 million fourth quarter loss as the health insurer exits unprofitable Medicare Advantage markets for 2025.

The e-commerce platform beats quarterly estimates for revenue and gross merchandise volume.

Salesforce is expected to roll-out full version of its largely anticipated Agentforce 2.0 offering, which is extremely likely to be a game-changer in terms of the share price. Apart from the expected Agentforce 2.0 full release, there are several other developments emphasizing the management's strong focus on AI. My valuation analysis suggests that the stock is significantly undervalued.

Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=128741&wire=1 or contact Joseph E. Levi, Esq.

MIAMI, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Digihost Technology Inc. (“Digihost” or the “Company”) (Nasdaq / TSXV: DGHI), is proud to announce the formation of US Data Centers, Inc. (“US Data Centers”), a wholly-owned subsidiary of the Company which will be dedicated to the development of high-performance computing (“HPC”) and artificial intelligence (“AI”)-focused data centers. The new US Data Centers website can be found at www.usdatacenters.ai.

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Crocs, Inc. (NASDAQ:CROX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/crocs-inc-lawsuit-submission-form?prid=128743&wire=1 or contact Joseph E. Levi, Esq.

Medicus Pharma Ltd.'s shares will remain listed on the NASDAQ Capital Market Medicus Pharma Ltd.'s shares will remain listed on the NASDAQ Capital Market

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your FTAI Aviation Ltd. (NASDAQ:FTAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ftai-aviation-ltd-lawsuit-submission-form?prid=128742&wire=1 or contact Joseph E.

BEIJING, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cheer Holding, Inc. (NASDAQ: CHR) (“Cheer Holding” or the “Company”), a leading provider of advanced mobile internet infrastructure and platform services, today announced a major upgrade to its CHEERS video platform (“CHEERS”). As consumer demand for personalization in the home goods market continues to rise, coupled with a younger and more personalized user base, the need for diverse and refined functional home solutions is increasing. as a premier lifestyle content aggregation platform, CHEERS is keenly attuned to market changes and has undergone a critical upgrade and optimization since its launch.

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=128740&wire=1 or contact Joseph E. Levi, Esq.

DuPont cited continued recovery in semiconductor demand, driven primarily by AI-technology applications and stronger demand in China, for its results.

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated for FSGS, a rare kidney disorder and leading cause of kidney failure sNDA submission to be based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS Company to host conference call and webcast today at 8:30 a.m. ET SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the Company has completed its Type C meeting …